Seeking Alpha

AEterna Zentaris (AEZS) is a small cap drug development company. Like many drug development companies, it has had its share of success and failures over the years. However, the company now appears to be significantly undervalued when compared to the pipeline that it has in development. With the company expected to file an NDA soon and initiating another Phase III trial, the next year or so will provide a multitude of interesting catalysts that should help to drive share price growth. Coupled with the company's financial position, this share price increase should be sustainable and should be able to provide significant returns for long term oriented investors.

AEZS-130

AEZS-130 is a test developed by AEterna for the diagnosis...

Only subscribers can access this article, which is part of the PRO research library covering 3,758 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: